- anyone claiming NWBO has the compassionate right to sell DCVAXL other than GBM indication is spreading falsehoods.
- anyone claiming NWBO's HALTED and NON-CONTINUED in the past L or D trials will contribute to its valuation if NWBO is acquired is spreading falsehoods, and does not know what he is talking about
- all nonrevenue biotech are in possession of intellectual property, if they didn't they would be worth zilch. There is nothing special about a biotech owning IP/Patents. Immunomedics had plenty of IP/Patents before it was acquired.
- anyone claiming NWBO will be approved for other cancer indications outside GBM without additional trials, is spreading falsehoods. Immunomedics had 2 other P3 trials just before it was bought. MWBO has NON.
- Current combo DCVAX trials are sponsored by UCLA NOT NWBO although NWBO holds the IP.
- DCVAX is NOT a platform as long as NWBO has not conducted other trials for other cancer indications based on which outcome RA's will grant NWBO approval for those other indications.

so your estimate of NWBO's acquiring value is based on cases where the total outstanding shares of the acquiring company could very well increase by 25% to purchase a new company? Those biotech companies that have been required by issuing 25% of O/S may very well have generated $300, $400 million in revenue prior to being bought.... Do you or anyone have an example of NONrevenue biotechs that were acquired above $ 25 billion with a single approved product? Ever?

But NWBO would be the first then? Not going to happen.

Hi Mionaer

I still stand by my previous estimate
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172048843

************************
I am expecting Merck to pay the same for NWBO as Gilead paid for Immunomedics so $21 billion but perhaps +$3 billion extra =24Billion
https://www.reuters.com/article/us-immunomedics-m-a-gilead-sciences-idUSKBN2640V8

In my view, Immunomedics can be very well compared to NWBO
Just like NWBO Immunomedics was an almost zero (20 million) revenue biotech
Just like NWBO Immunomedics claimed to have a platform for solid tumors
Immunomedics catered to a much bigger market (Immunomedics Trodelvy is for breast cancer) than NWBO however with many more competitors.
Just like NWBO Immunomedics claimed Trodelvy can be used for all solid tumors
Just like NWBO Immunomedic had not started any meaningful P3 trial to provide evidence that Trodelvy is actually effective for all solid tumors

So with 1.5 billion shares O/S (1.1 now + 100 million max more dilution + 250 million for NWBO management) that would get us to around $ 16 per share buyout
****************************

No argument there :)

100% agree

Im more annoyed by NWBO zealots pushing fantasy fairytales than by the shorts/bears spreading nonsense. The latter is way less devastating for new longs than the first. Zealot fantasy fairytales completely out of touch with reality harvest great disappointment among longs that believe the out-of-touch stories.

You gave an accurate description of how future DCVAXL trials could be conducted.
Personally, I do not believe NWBO will and is capable of ever starting any new DCVAX L trial for new cancer indications. Merck will (after it bought NWBO after DCVAXL has been approved for GBM).

From NWBO's last 10Q:
In the future, we plan to conduct clinical trials of DCVax-L for other types of solid tumor cancers, beyond brain cancer, when resources permit.


But according to you, NWBO is lying and you know better than NWBO itself?
Perhaps you should send an email to NWBO that their 10Q contains a falsehood that there is no need for other DCVAXL clinical trials for other types of solid tumor cancers, beyond brain cancer, for surely the RA will provide NWBO approval for all solid tumors without the trails NWBO itself says it is panning.

My friend has been assured that as well, as I have been saying here a few times already.

Of course, no one knows for 100% but I'm convinced NWBO will be bought a few months after approval (FDA or MHRA). Its a fact that Direct is Bosch's life work and Im convinced he wants to continue working on it after NWBO has been acquired.

Why you think he would not want to move back to the US to continue his life work is a guess. If your provided reason is retirement in Europe then that is also true also for him yes or no working for NWBO as lead investigator/CTO for the Direct trial in the future. Why would that be any different? In other words, if you think Bosch will retire in Europe then you also think NWBO will be bought. I just happen to think Bosch wants to work for Merck after they bought NWBO.

If you want to know the reason why the application is taking so long then read page 23 of the last 10Q its right there is nothing mysterious about it

https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057823000976/nwbo-20230331x10q.htm

Bosch was presenting himself to Merck as lead investigator for the DCVAX trials Merck will conduct after they bought NWBO 3-6 months after MHRA approval.

I think its safe to say they really dont want us to know what they will communicate: the submitting, acceptance or the approval itself.

lol

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
or
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA: PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients
or
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility
or
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

Dave = USELESS

or

He was talking about DCVAXL not DCVAXD

Anyway sure anything is possible in the future but the suggestion is being made that they are applying for approval for DCVAXL on Tissue Agnostic basis which will not happen without additional trials.

Again, as two weeks ago, false news is being spread. Two weeks ago it was NWBO has the right to sell compassioned use for all solid tumors now its they are applying for tissue agnostic

so NWBO in its last 10Q was lying when it said this:

DCVAX combats cancer and is a cancer treatment. The correlation between alcohol consumption and cancer has been proven in many scientific studies. An Alcohol bar environment is not the appropriate venue to promote DCVCAX.

Anyone calling that a fabricated narrative is narrow-minded.

Someone saying that its a laughable narrative that alcohol is a cause of great medical problems among others different types of cancer and also many social problems tells you everything you need to know about the character of that person.

Les in the big Vodka show is cheap and sleazy.

Also, I remind everyone that promoting DCVAX by Les in a room filled with alcohol (alcohol increases the risk of cancer dramatically) screams of poor taste, and an immense lack of knowledge of modern health issues associated with the use of alcohol.

For a biotech company combating cancer presenting itself in a bar surrounded by alcohol just demonstrates poor taste and a complete and utter lack of respect for medical doctors combating the health implications caused by alcohol every day.


https://biztalkwithscore.com/enjoying-people-through-beer-and-food

https://www.cdc.gov/cancer/alcohol/index.htm#:~:text=Why%20Does%20Alcohol%20Use%20Raise,cell's%20normal%20growth%20and%20function.

even SOS two moths prediction made on APR 11, 2023 to finalize the MAA has come and go

Les on the Bud Beer show screams of desperation. They have nothing to show for, we are in for a long wait still.